Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2018

Jaiswal Bijay S, Durinck Steffen, Stawiski Eric W, Yin Jianping, Wang Weiru, Lin Eva, Moffat John, Martin Scott E, Modrusan Zora, Seshagiri Somasekar

Abstract excerpt

Purpose: MAPK pathway inhibitors targeting BRAF and MEK have shown clinical efficacy in patients with RAF- and/or RAS-mutated tumors. However, acquired resistance to these agents has been an impediment to improved long-term survival in the clinic. In such cases, targeting ERK downstream of BRAF/MEK has been proposed as a potential strategy for overcoming acquired resistance. Preclinical studies suggest that ERK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to HCT116 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Receptor, ErbB-2

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 29760222
DOI: 10.1158/1078-0432.CCR-17-3674

Genes

BRAF
EGFR
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.PMID 29760222Read ↗

ERK inhibition overcomes acquired resistance to MEK inhibitors.Semantic proximity Read ↗

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.Semantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).Semantic proximity Read ↗

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKSemantic proximity Read ↗

ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.Semantic proximity Read ↗

Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art.Semantic proximity Read ↗

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Semantic proximity Read ↗

The MEK/ERK Network as a Therapeutic Target in Human CancerSemantic proximity Read ↗

Targeting pathological ERK1/2 signaling in cancer and beyondSemantic proximity Read ↗

Towards a unified model of RAF inhibitor resistance.Semantic proximity Read ↗

ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.